BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 25468813)

  • 21. Search for accumulation of p53 protein and detection of human papillomavirus genomes in sebaceous gland carcinoma of the eyelid.
    Hayashi N; Furihata M; Ohtsuki Y; Ueno H
    Virchows Arch; 1994; 424(5):503-9. PubMed ID: 8032531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. UV-independent p53 mutations in sebaceous carcinoma of the eyelid.
    Hussain RM; Matthews JL; Dubovy SR; Thompson JM; Wang G
    Ophthalmic Plast Reconstr Surg; 2014; 30(5):392-5. PubMed ID: 24777261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene.
    Pelosi G; Gasparini P; Cavazza A; Rossi G; Graziano P; Barbareschi M; Perrone F; Barberis M; Takagi M; Kunimura T; Yamada T; Nakatani Y; Pastorino U; Scanagatta P; Sozzi G; Garassino M; De Braud F; Papotti M
    Lung Cancer; 2012 Sep; 77(3):507-14. PubMed ID: 22705117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
    Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
    Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
    Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
    Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
    Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
    Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
    Shigematsu H; Takahashi T; Nomura M; Majmudar K; Suzuki M; Lee H; Wistuba II; Fong KM; Toyooka S; Shimizu N; Fujisawa T; Minna JD; Gazdar AF
    Cancer Res; 2005 Mar; 65(5):1642-6. PubMed ID: 15753357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab.
    Lee HJ; Kim JY; Park SY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
    Am J Clin Pathol; 2015 Oct; 144(4):570-8. PubMed ID: 26386078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [HER2 gene amplification and overexpression in advanced gastric cancer].
    Roa I; Slater J; Carvajal D; Schalper K; de Toro G; Ares R; Game A; León J; de Aretxabala X
    Rev Med Chil; 2013 Nov; 141(11):1411-9. PubMed ID: 24718467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ZEB2/SIP1 as novel prognostic indicator in eyelid sebaceous gland carcinoma.
    Bhardwaj M; Sen S; Sharma A; Kashyap S; Chosdol K; Pushker N; Bajaj MS; Bakhshi S
    Hum Pathol; 2015 Oct; 46(10):1437-42. PubMed ID: 26220160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER2 and EGFR gene copy number alterations are predominant in high-grade salivary mucoepidermoid carcinoma irrespective of MAML2 fusion status.
    Nakano T; Yamamoto H; Hashimoto K; Tamiya S; Shiratsuchi H; Nakashima T; Nishiyama K; Higaki Y; Komune S; Oda Y
    Histopathology; 2013 Sep; 63(3):378-92. PubMed ID: 23855785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry.
    Pellegrini C; Falleni M; Marchetti A; Cassani B; Miozzo M; Buttitta F; Roncalli M; Coggi G; Bosari S
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3645-52. PubMed ID: 14506153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization: comparison with immunohistochemistry.
    Kounelis S; Kapranos N; Malamos N; Kouri-Bairaktari E
    Anticancer Res; 2005; 25(2A):939-46. PubMed ID: 15868931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation.
    Sekido Y; Umemura S; Takekoshi S; Suzuki Y; Tokuda Y; Tajima T; Osamura RY
    Int J Oncol; 2003 Jun; 22(6):1225-32. PubMed ID: 12738987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
    Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
    Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene amplification and protein overexpression of EGFR and ERBB2 in sinonasal squamous cell carcinoma.
    López F; Llorente JL; Oviedo CM; Vivanco B; Marcos CÁ; García-Inclán C; Scola B; Hermsen MA
    Cancer; 2012 Apr; 118(7):1818-26. PubMed ID: 22009799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer.
    Lee HJ; Seo AN; Kim EJ; Jang MH; Suh KJ; Ryu HS; Kim YJ; Kim JH; Im SA; Gong G; Jung KH; Park IA; Park SY
    Am J Clin Pathol; 2014 Dec; 142(6):755-66. PubMed ID: 25389328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays.
    McCormick SR; Lillemoe TJ; Beneke J; Schrauth J; Reinartz J
    Am J Clin Pathol; 2002 Jun; 117(6):935-43. PubMed ID: 12047146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
    Jimenez RE; Wallis T; Tabasczka P; Visscher DW
    Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.